XY0206 targets FLT3-dependent resistance states in acute myeloid leukemia.
Long Shen, Yang Yang, Chenghua Xu et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I/II clinical trial evaluated XY0206 monotherapy in patients with relapsed or refractory acute myeloid leukemia (AML), alongside laboratory and animal studies of its FLT3-directed activity. XY0206 suppressed FLT3-associated signaling and retained activity in models of resistance, including cells with the F691L mutation. In the clinical trial, the overall composite complete remission rate was 45.7%; among patients with FLT3-ITD mutations, it was 60.0%. Three of 8 patients previously exposed to FLT3 inhibitors achieved composite complete remission.
Key findings
- The composite complete remission rate was 45.7% overall and 60.0% among patients with FLT3-ITD mutations.
- Three of 8 patients with relapsed or refractory AML previously exposed to FLT3 inhibitors achieved composite complete remission.
- XY0206 retained antileukemic activity in resistance models, including FLT3-ITD cells with the F691L gatekeeper mutation.
- In primary AML blasts and xenograft models, XY0206 showed enhanced antileukemic activity and favorable tolerability relative to gilteritinib.
Why it matters
Resistance to existing FLT3 inhibitors can limit treatment options in AML. The reported remission rates, including responses after prior FLT3 inhibitor exposure, provide clinical evidence that XY0206 warrants further evaluation in this setting. Its activity in models carrying a resistance-associated FLT3 mutation also supports investigation of whether it may address some mechanisms of reduced inhibitor sensitivity.
What to keep in mind
The abstract does not report the clinical trial sample size, response durability, or comparative clinical outcomes; the clinical findings are from a phase I/II trial of monotherapy.